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What’s in a Name? Classification of Diabetes Mellitus in Veterinary
Medicine and Why It Matters
C. Gilor, S.J.M. Niessen, E. Furrow, and S.P. DiBartola
Diabetes Mellitus (DM) is a syndrome caused by various etiologies. The clinical manifestations of DM are not indicative
of the cause of the disease, but might be indicative of the stage and severity of the disease process. Accurately diagnosing
and classifying diabetic dogs and cats by the underlying disease process is essential for current and future studies on early
detection, prevention, and treatment of underlying disease. Here, we review the current etiology-based classification of DM
and definitions of DM types in human medicine and discuss key points on the pathogenesis of each DM type and predia-
betes. We then review current evidence for application of this etiology-based classification scheme in dogs and cats. In dogs,
we emphasize the lack of consistent evidence for autoimmune DM (Type 1) and the possible importance of other DM types
such as DM associated with exocrine pancreatic disease. While most dogs are first examined because of DM in an insulin-
dependent state, early and accurate diagnosis of the underlying disease process could change the long-term outcome and
allow some degree of insulin independence. In cats, we review the appropriateness of using the umbrella term of Type 2 DM
and differentiating it from DM secondary to other endocrine disease like hypersomatotropism. This differentiation could have
crucial implications on treatment and prognosis. We also discuss the challenges in defining and diagnosing prediabetes in
cats.
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What Is Diabetes Mellitus?
Diabetes Mellitus (DM) is not a single disease, but asyndrome characterized by hyperglycemia that
results from defects in insulin secretion or insulin sensi-
tivity in target tissues or both.1 Several pathogenic pro-
cesses can lead to development of DM, from
autoimmune destruction of pancreatic b-cells with con-
sequent absolute insulin deficiency to abnormalities that
result in resistance to insulin action such as hypersoma-
totropism. Regardless of cause, deficiency in insulin or
its action on target tissues leads to a myriad of abnor-
malities in carbohydrate, fat, and protein metabolism.
Abnormalities in insulin secretion and action frequently
coexist in the same individual, and often it is impossible
to determine which abnormality is the primary cause of
the hyperglycemia. Also, deficits in insulin secretion are
not necessarily merely a consequence of insulin resis-
tance in individuals with type 2 DM (T2DM). The pres-
ence and magnitude of hyperglycemia can change over
time, depending on the extent of the underlying disease
process and associated comorbidities. A disease process
could cause prediabetes (see definition later) without
progressing to overt diabetes.1 Thus, the clinical and
clinicopathologic manifestations of DM are not indica-
tive of the cause or causes of the disease, but might be
indicative of the stage and severity of the disease pro-
cess. In this respect, it seems prudent to consider the
diagnosis of DM as analogous to a diagnosis of other
end-stage organ failures like chronic renal failure or
hepatic cirrhosis.
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Abbreviations:
ADA American Diabetes Association
BG blood glucose concentration
DLA dog leukocyte antigen
DM diabetes mellitus
FPG fasting plasma glucose concentration
FPIR first phase insulin response
fPLI feline pancreatic lipase activity
GH growth hormone
GIP glucose-dependent insulinotropic peptide
GLP-1 glucagon-like peptide-1
HbA1c hemoglobin A1c concentration
HLA human leukocyte antigen
HNF hepatocyte nuclear factor
IDDM insulin-dependent diabetes mellitus
IFG impaired fasting glucose
IGF-1 insulin-like growth factor-1concentrations
IGT impaired glucose tolerance
IVGTT IV glucose tolerance test
MODY mature-onset diabetes of the young
NIDDM noninsulin-independent diabetes mellitus
OGTT oral glucose tolerance test
PGHDM progesterone-controlled GH overproduction DM
PP pancreatic polypeptide
RI reference Interval
T1DM type 1 DM
T2DM type 2 DM
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Accurately diagnosing and classifying diabetic dogs
and cats by the underlying disease process is essential
for current and future studies on treatment methods,
early detection, treatment of underlying disease, and
prevention. Neonatal DM in people provides an exam-
ple of how the specific underlying etiology can impact
treatment recommendations. Until recently, diabetic
neonates were considered insulin-dependent and prone
to ketosis. This clinical presentation led to categorizing
them as having insulin-dependent diabetes mellitus
(IDDM) or type 1 DM (T1DM). Children therefore
were relegated to life-long exogenous insulin treatment.
This changed when it was discovered that most neona-
tal DM patients carry mutations in genes encoding the
b-cell KATP channel. Once diagnosed correctly, such
patients can be managed with oral sulfonylurea drugs,
which allow them to become insulin-independent,
achieve superior glycemic control and experience
improved quality of life.2 Similarly, advances in the
study of autoimmune DM (T1DM) now allow targeted
therapy that slows progression of the disease and
decreases insulin requirements if used early enough in
the disease process.3,4 On the horizon are diagnostic
tests for earlier detection of T1DM as well as studies on
the prevention of the disease before establishment of an
autoimmune state.5
Classification of Diabetes Mellitus: Historical
Perspective
The clinical manifestations of DM were first
described by the Greeks over 2,000 years ago. From the
first demonstration of lesions in the islets of Langerhans
by Opie (1901) to the first successful use of insulin ther-
apy by Banting and Best (1922), and throughout most
of the 20th century, DM was classified based on clinical
manifestations as juvenile or adult onset. In 1979, the
National Diabetes Data Group proposed a new 3 cate-
gory classification based on clinical manifestations and
insulin requirement necessary to prevent ketosis: Insu-
lin-dependent DM (IDDM, or juvenile DM, prone to
ketosis), noninsulin-independent (NIDDM, or mature-
onset DM, including Mature-Onset Diabetes of the
Young [MODY], not prone to ketosis), and others
(DM secondary to pancreatitis, endocrinopathies, drugs,
and other causes).6 Impaired glucose tolerance (IGT)
and Gestational DM were classified separately.6
With increased understanding of the pathophysiology
of DM toward the end of the 20th century, the termi-
nology of IDDM and NIDDM was slowly replaced by
type 1 and type 2 DM. Initially, the clinical categoriza-
tion overlapped completely with etiologic type (ie,
IDDM was termed type 1 and NIDDM was termed
type 2), but at the turn of the century, the consensus
was to adopt an etiology-based classification and the
terms IDDM and NIDDM were abandoned.7
An up-to-date classification of DM from the Ameri-
can Diabetes Association (ADA) is presented in
Table 1.1 In this etiology-based classification, regardless
of the underlying disease process, DM begins with a
subclinical phase in which euglycemia is maintained,
but abnormalities in b-cell function or mass already are
present. As the disease progresses, glucose intolerance
(impaired fasting glucose [IFG], IGT, or both) can be
detected and a diagnosis of prediabetes made. With fur-
ther progression, glucose intolerance worsens until the
criteria for a diagnosis of DM are met. The line
between prediabetes and DM however is arbitrary, and
glucose intolerance progresses as a continuum (see later:
Prediabetes and diabetes risk). In the diabetic state,
insulin therapy might or might not be required, and the
requirement could be permanent, transient, or recurring.
Whether or not insulin is required, therefore does not
define the disease category and is not unique to a
disease category.1 For example, although most patients
with T1DM are insulin-dependent, they often experi-
ence a transient phase of insulin independence.
Similarly, most people with T2DM initially are insulin-
independent, but ultimately proceed to requiring insulin.
Most often, this insulin-requiring state is temporary in
T2DM, but also could become permanent.
Key features of each type of DM and prediabetes
based on the current ADA classification are presented
in the next section and subsequently are discussed in
the context of DM in dogs and cats.1
Table 1. Etiologic classification of diabetes mellitus
based on the American Diabetes Association (rare
etiologies were not included).1
Type Abbreviated description of etiology
1 b-cell destruction, usually leading to absolute
insulin deficiency
a. Immune-mediated
b. Idiopathic
2 Unknown etiology. A combination of insulin
secretory defect with insulin resistance
(Relative insulin deficiency)
Others a. Monogenic defects of b-cell function:
MODY 1-8: Mutations in HNF-1, HNF-4,
glucokinase, and others
Transient neonatal: Mutations in
ZAC/HYAMI
Permanent neonatal: Mutations in KCNJ11
b. Genetic defects in insulin action
c. Diseases of the exocrine pancreas
d. Endocrinopathies:
Insulin resistance (hypersomatotropism,
hypercortisolism, others)
Decreased insulin secretion
(somatostatinoma, others)
e. Drug or chemical induced
(diazoxide, cyclosporine, tacrolimus, others)
f. Infections
g. Uncommon forms of immune-mediated
diabetes mellitus (Anti-insulin receptor
antibodies, Stiff-man syndrome, others)
h. Other genetic syndromes associated with
diabetes (Down, PW, others)
Gestational A state of increased insulin resistance
superimposed on an already existing state
of b-cell dysfunction or loss
Prediabetes Intermediate stages in the disease processes
of any of the above types
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Classification of Diabetes Mellitus in Human
Medicine
Overt diabetes mellitus (as opposed to prediabetes) is
defined as a fasting plasma glucose concentration
(FPG) ≥ 126 mg/dL (7 mmol/L), a plasma glucose con-
centration ≥ 200 mg/dL (11.1 mmol/L) 2 h after oral
glucose administration, or a hemoglobin A1c concentra-
tion (HbA1c) > 6.5%.
8
Type 1 Diabetes Mellitus: Beta Cell Destruction
Typically Leading to Absolute Insulin Deficiency
Immune-Mediated Diabetes Mellitus. This form of
T1DM results from cell-mediated autoimmune destruc-
tion of the pancreatic b-cells. In people, markers of the
immune destruction of b-cells include several islet cell
autoantibodies (GAD65, IA-2, and ZnT8) and autoanti-
bodies to insulin.9 Ninety-eight percent of T1DM peo-
ple are autoantibody positive.8 Two or more of these
autoantibodies are present in 85–90% of T1DM
patients when fasting hyperglycemia is detected, and
antibodies can be detected years before onset of clinical
disease. The antibody profile is highly predictive of the
rate of progression to overt DM.9
The disease has strong human leukocyte antigen
(HLA) class II associations, with linkage to the DQA1,
DQB1, and DRB1 genes.10 These HLA-DR/DQ alleles
can be predisposing or protective, and account for most
of the heritability observed in T1DM. Several genes
involved in T-cell function, including PTPN22, CTLA4,
and IL2RA, also impart risk of T1DM. The insulin
gene, INS, is another major non-HLA susceptibility
gene, and polymorphisms in INS are strongly associated
with the presence of insulin autoantibodies at diagno-
sis.9 T1DM also is associated with other autoimmune
disorders, including endocrine diseases as well as myas-
thenia gravis, autoimmune hepatitis, and inflammatory
bowel disease.1,8
The rate of b-cell destruction is variable in immune-
mediated DM. Whereas rapid progression is seen in
juveniles, the disease progresses slowly in adults, and
residual b-cell function might be retained for years.1 In
contrast to the original definition of juvenile-onset
DM, 50% of T1DM patients are adults (>20 years of
age).8,11 The disease in adults can be easily confused
with T2DM because b-cell function often is sufficient
to prevent ketoacidosis. Eventually, these patients
become dependent on insulin. The “honeymoon phase”
(a transient and partial remission phase in which a pre-
viously insulin-dependent patient does not require insu-
lin therapy) often lasts 3–6 months, but might continue
for 2 years, and occurs in up to 60% of T1DM
patients.12
Idiopathic DM. In this subtype 1 DM, there is evi-
dence of b-cell destruction, but without evidence of
autoimmunity. An absolute requirement for insulin
therapy can be intermittent. A minority of T1DM
patients falls into this category and most are of African
or Asian ancestry. This form of DM is strongly inher-
ited, lacks features of b-cell autoimmunity, and is not
HLA-associated. For these reasons, recently the ADA
excluded this subtype from the T1DM class.8
Type 2 DM: Unknown Etiology. Pathogenesis: A
Combination of Insulin Secretory Defect with Insulin
Resistance
Type 2 DM previously was encompassed by
NIDDM or adult-onset DM. Its pathogenesis is char-
acterized by a combination of impaired insulin secre-
tion with insulin resistance (relative insulin deficiency).
Initially (and often throughout life), these patients do
not require insulin treatment to survive. Although the
specific etiologies are not known, autoimmune destruc-
tion of b-cells does not occur, and patients do not have
any of the other causes of DM listed below for other
specific types (ie, T2DM is a diagnosis of proactive
exclusion).
Several mechanisms have been suggested as partial
explanations for the abnormalities in glycemic control
observed in T2DM patients, including amylin misfold-
ing and amyloid deposition, decreased b-cell mass,
b-cell dysfunction, decreased sensitivity to glucose, and
a-cell dysfunction.7 Not all of these abnormalities are
consistently present nor do they have the same degree
of severity in all T2DM patients. Furthermore, the
inciting lesions have not been clearly distinguished from
the pathologic sequelae. Nevertheless, the various com-
binations of abnormalities likely represent different dis-
ease etiologies underlying T2DM. T2DM is a diagnosis
of exclusion; whenever a primary disease process is
identified, this type of DM is automatically excluded
from the umbrella term T2DM and reclassified (see for
example MODY below).
Most patients with T2DM are obese either by tradi-
tional weight criteria or by increased body fat in the
abdominal region (ie, visceral obesity).7 Although obe-
sity causes insulin resistance, in itself it is not the cause
of T2DM. In nondiabetic people, obesity results in a
compensatory response in b-cells and a subsequent
increased capacity to secrete insulin. Obese people
remain euglycemic, but with increased insulin concen-
trations. In human autopsy studies, obese nondiabetic
subjects have a 50% increase in relative b-cell volume.13
In T2DM, this compensatory response to insulin resis-
tance fails because of an intrinsic abnormality in b-cells.
Although T2DM patients could have plasma insulin
concentrations that are normal or increased, they are
not as high as expected based on their blood glucose
concentrations (BG). Insulin sensitivity might improve
with weight reduction, pharmacologic interventions, or
both, but it rarely normalizes.
Other risk factors for developing T2DM include
aging and lack of physical activity. T2DM occurs more
frequently in women with prior Gestational DM and in
people with hypertension or dyslipidemia, and its fre-
quency differs among ethnic groups. T2DM has a stron-
ger genetic predisposition than autoimmune T1DM,
with heritability up to 80%.14 However, specific genetic
risk factors for T2DM are diverse and complex, and
remain to be fully elucidated.
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Other Specific Types of DM
Monogenic Defects of the b-Cells. Several forms of
DM are associated with monogenic defects in b-func-
tion. This potentially is the most important category for
clinicians to recognize.15 Identification of the causative
mutation can affect treatment recommendations and
allow insulin therapy to be replaced by alternative phar-
macologic interventions.15
Neonatal DM: Transient or Permanent. In contrast to
past assumptions, DM diagnosed in the first 6 months
of life in people is not caused by an autoimmune
process and these patients are not necessarily insulin-
dependent. Transient neonatal DM is characterized by
hyperglycemia that begins in the neonatal period and
resolves by 18 months of age.16 The most common
cause is a genetic defect at the 6q24 locus, resulting in
overexpression of the genes that regulate insulin secre-
tion, b-cell proliferation, and peripheral insulin sensitiv-
ity.16,17 Permanent neonatal DM is a distinct condition
commonly caused by mutation in the genes (KCNJ11
and ABCC8) that encode subunits of the b-cell KATP
channel. Children with this type of DM are not insulin-
dependent; sulfonylurea therapy results in superior gly-
cemic control.2
Maturity Onset Diabetes of the Young. Maturity
onset diabetes of the young is characterized by impaired
insulin secretion with minimal or no defects in insulin
action. Affected patients typically are nonobese young
adults (<25 years old). Genes implicated in MODY are
crucial in b-cell development, function and regulation,
as well as glucose sensing, and include the insulin
gene.18 The causative mutations are inherited in an
autosomal dominant pattern. Up to 80% of MODY
cases are caused by mutations in the glucokinase and
hepatocyte nuclear factor (HNF1A and HNF4A)
genes.19 Treatment varies based on the underlying
genetic defect. For example, patients with glucokinase
gene mutations might have only mild hyperglycemia
and not require any treatment, whereas those with
HNF1A or HNF4A mutations require sulfonylurea ther-
apy and might progress to insulin dependence.19 Before
genetic characterization, these patients were classified as
having T2DM because the diagnosis was made in
autoantibody-negative NIDDM adults.
Genetic Defects in Insulin Action. Genetic disorders
of insulin receptors or postreceptor defects are uncom-
mon in people and have not been reported in
animals.1,7
Diseases of the Exocrine Pancreas. Any process that
diffusely injures the pancreas has the potential to cause
DM. Acquired processes include pancreatitis, trauma,
infection, pancreatectomy, and pancreatic neoplasia.
Damage to the pancreas must be extensive before dia-
betes ensues (This type of DM is discussed more exten-
sively below in the section relating to DM in dogs).
Endocrinopathies. Endocrinopathies that lead to
severe insulin resistance can cause DM (eg, hypersoma-
totropism, hypercortisolism, glucagonoma, and pheoch-
romocytoma). In these diseases, DM typically develops
in people with preexisting defects in insulin secretion,
but hyperglycemia might resolve when hormone concen-
trations normalize.15 Rarely, DM is caused by non-b-
cell endocrinopathies that decrease insulin secretion (eg,
aldosteronoma-induced hypokalemia and somatostati-
nomas). Hyperglycemia generally resolves after removal
of the tumor.
Gestational DM
For many years, Gestational DM was defined as glu-
cose intolerance that is first recognized during preg-
nancy, without distinguishing between cases in which
glucose intolerance antedated pregnancy and those in
which it developed concomitantly with pregnancy.
Recently, the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) recommended that
high-risk women found to have DM at their initial pre-
natal visit receive a diagnosis of overt, not Gestational,
DM.20 Thus, the diagnosis of Gestational DM is
reserved for women that have had no evidence of DM
in early pregnancy but developed it later during
pregnancy. Most Gestational DM cases resolve after
delivery.1
Gestational DM is an important diagnosis because it
is associated with increased risk of complications during
late pregnancy, abnormalities in the newborn, and
future T2DM in the mother. Gestational DM represents
a state of increased insulin resistance superimposed on
an already existing state of b-cell dysfunction or loss.15
Late in pregnancy, the human placenta secretes human
placental lactogen and tumor necrosis factor-a, which
lead to insulin resistance. As a result, insulin secretion
increases to maintain euglycemia. Any cause of b-cell
dysfunction or loss (ie, independent of etiology) could
prevent this compensatory increase in secretion and lead
to glucose intolerance or overt DM.15
Prediabetes and Diabetes Risk
Prediabetes is defined as a condition in which hyper-
glycemia is present but does not meet criteria for DM.
One or both of the following abnormalities are used to
characterize a patient with prediabetes:
Impaired fasting glucose (IFG): FPG concentrations
of 100–125 mg/dL (5.6–6.9 mmol/L).
Impaired glucose tolerance (IGT): 2-hour plasma glu-
cose concentrations during an oral glucose tolerance
test (OGTT) of 140–199 mg/dL (7.8–11.0 mmol/L).
Prediabetes (IFG, IGT, or both) indicates a high risk
for the future development of DM as well as cardio-
vascular disease. IFG and IGT can be observed as
intermediate stages in the disease processes of any DM
type (type 1, 2, or others) and are associated with obe-
sity (especially visceral obesity), dyslipidemia, and
hypertension. Structured lifestyle intervention, increas-
ing physical activity and 5–10% loss of body weight,
as well as specific pharmacologic interventions can
prevent or delay development of DM in people with
prediabetes.
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Prospective studies have identified a strong, continu-
ous association between measures of glycemia and
development of DM. Thus, the aforementioned cutoffs
for IFG and IGT are arbitrary and intended merely to
facilitate classification and enable comparison of stud-
ies. Studies on HbA1c (glycated hemoglobin) further
demonstrate the continuum of risk for DM.21 People
with HbA1c above the laboratory reference interval
(6.0–6.5%), but below the diagnostic cut-off for DM
(>6.5%) have a high incidence of DM with 10-fold the
risk of the general population. However, individuals at
the high end of the RI (ie, 5.5–6.0%) also have a 3–8
fold increased risk. Therefore, preventive interventions
are recommended at HbA1c > 5.5% even though results
might fall within the normal range.
Classification of Diabetes Mellitus in Veterinary
Medicine
The classification system of IDDM and NIDDM was
adopted by veterinary medicine in the 20th century and,
as in human medicine, subsequently was replaced by
the terminology types 1 and 2. At that time, however,
the rationale for this change in terminology was not
uniformly adopted. Many veterinarians continued to
use the terminology Types 1 and 2 as equivalent to
IDDM and NIDDM, regardless of the underlying
etiopathogenesis. This is explained partially by the still
modest (but gradually increasing) level of understanding
of the underlying disease processes in the field of veteri-
nary diabetology. Several questions arise when trying to
apply the current DM classification based on etiopatho-
genesis to companion animals. What are the actual
causes of DM in dogs and cats, and do the causes actu-
ally affect treatment? If so, how? Would a better under-
standing of the etiopathogenesis of DM in dogs and
cats enable intervention at early stages leading to slow-
ing progression, avoiding insulin dependence or even
preventing DM altogether?
How Do Past and Current Classification Systems
Apply to DM in Dogs?
An exact definition of DM in dogs has not been
agreed upon and also is made difficult by the many dif-
ferent biochemical analyzers and glucometers used in
veterinary medicine. These same issues however have
not prevented a reasonable and accepted compromise
definition in human diabetology. We therefore suggest
that overt DM in dogs be defined based on persistently
increased fasting BG (for example >144 mg/dL
[8 mmol/L]). The cutoff itself is arbitrary (a deviation
by 1mmol/L from the cutoff in people) and is meant
simply as a tool for standardization. As was the case in
people, we expect any suggested cutoff to be refined and
redefined as new data from future research become
available. Colleagues are encouraged to support and
adopt this definition, or to propose a superior defini-
tion. Simply maintaining the current status quo (ie,
absence of an exact definition) limits advancement in
the field.
T1DM: Does Autoimmunity Cause Adult-Onset
DM in Dogs?
Diabetes mellitus in dogs is commonly characterized
by permanent hypoinsulinemia, no increase in c-peptide
in response to insulin secretagogues, and an absolute
requirement for exogenous insulin administration to
avoid ketoacidosis.22 This presentation is consistent
with T1DM, but can also occur with most other types
of DM, depending on the stage of disease and severity
of glucotoxicity. Glucotoxicity refers to structural and
functional damage in pancreatic b-cells and the target
tissues of insulin caused by chronic hyperglycemia. This
phenomenon was demonstrated in human and rodent
models and most recently in cats.23 Dogs are also sensi-
tive to glucotoxicity and in its presence can become
hypoinsulinemic and diabetic despite having b-cell mass
that previously was sufficient to maintain eug-
lycemia.24,25 Fortunately, the detrimental effects of glu-
cotoxicity on b-cell function are reversible in the early
stages with aggressive treatment to normalize BG. Thus,
in a dog that is presented for clinical DM, the assump-
tion that the dog is suffering from end-stage T1DM (an
irreversible IDDM state) can result in a missed oppor-
tunity to treat and reverse glucotoxicity. This could be
important, for example, in dogs presented for acute
pancreatitis and no previous history of DM. If gluco-
toxicity is part of the pathology, aggressive treatment of
DM within a few weeks after diagnosis could lead to
sufficient recovery of b-cell function. However, if an
assumption is made that DM in this dog is T1DM (and
not DM secondary to disease of the exocrine pancreas)
then it is also assumed that this dog is at an end stage
of DM, and the dog would be treated with the current
standard of care: Controlling clinical signs without
attempting to achieve persistent euglycemia. This
approach represents a self-fulfilling prophecy in that less
than complete restoration of euglycemia will cause per-
manent damage to b-cells and lead to an irreversible
DM state. This example illustrates the flaws of this defi-
nition of T1DM and why it is important to search for a
specific etiology. Importantly, the hallmarks of T1DM
in people are not present in the majority of dogs with
DM.
Serologic and Histologic Evidence of Autoimmunity
There is evidence of cell-mediated autoimmune
destruction of b-cells in up to 50% of diabetic dogs26–30
in some studies whereas others have found no evidence
of autoimmune destruction.31–35 In a study evaluating
serum from 48 dogs with recently diagnosed but
untreated DM, autoantibodies reactive against the cyto-
plasmic content of normal canine islet cells were not
detectable in any sample.32 Similarly, a recent study
found no evidence of islet cell autoimmunity in 121 dia-
betic dogs of 40 different breeds.34 Only 5 dogs were
evaluated histologically, but none had lymphocytic (or
other) inflammation in the pancreatic islets. In an ear-
lier study, infiltrating mononuclear cells (predominantly
lymphocytes) were observed in 6 of 18 dogs (33%) with
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DM whereas in 5 dogs (28%), extensive pancreatic
damage appeared to be responsible for the development
of DM.28 An absence or decreased numbers of islets
together with degeneration and vacuolization but no
inflammation was described in 3 studies evaluating pan-
creatic histopathology in a total of 74 diabetic
dogs.31,33,35
A complicating factor in determining the prevalence
of autoimmune DM is that the presence of autoanti-
bodies and an inflammatory infiltrate depends on the
residual insulin content of the cells. Insulitis rarely is
detected once b-cells become insulin deficient.36 There-
fore, a plausible explanation for the relative lack of evi-
dence for autoimmunity in diabetic dogs could be that
most studies were performed using sera or tissue at a
late stage in the process when the insulin content of the
islets is too low for the immune system to amount a
detectable response. To date however, evidence support-
ing autoimmunity as a cause of DM in dogs is weak.
Genetic Evidence of Autoimmunity
DM in dogs is thought to be similar to T1DM based
on identification of specific susceptibility and protective
major histocompatibility complex haplotypes.37 Dog
leukocyte antigen (DLA) haplotypes have been identi-
fied that are more prevalent in breeds with a higher risk
for DM, such as the Samoyed, Tibetan terrier, and
Cairn terrier. Within breeds, however, these haplotypes
are common not only in diabetic dogs but, also in con-
trols. Other immune system genes associated with
T1DM in humans also have been implicated in canine
DM. Risk or protective variants have been identified in
IL-4 and other interleukin genes, PTPN22, CTLA4,
and INS. However, these data should be interpreted
cautiously because candidate gene approaches are asso-
ciated with a high risk of false positives in dogs. The
DLA locus can be particularly susceptible to false asso-
ciations as a consequence of overrepresentation of
genetic material from popular sires, high levels of
inbreeding, or genetic drift.34,38,39 In conclusion,
although a compelling body of genetic studies has accu-
mulated thus far, additional studies are necessary to
determine exactly how much the DLA locus and the
other aforementioned genes contribute to risk for
T1DM in dogs.
Based on the above studies, most diabetic dogs have
etiologies other than immune-mediated T1DM. What,
then, are the most likely causative factors of DM in
dogs?
T2DM in Dogs
Despite the increasing prevalence of obesity in dogs,
there is no evidence that insulin resistance unmasks
b-cell dysfunction with resulting DM as is the case in
people. Obese dogs show evidence of insulin resistance
but compensate appropriately through increased insulin
secretion.40 Even after years of obesity-induced insulin
resistance, DM does not appear to develop and most
obese dogs maintain euglycemia.
Genetic Defects of the b-cells Or Insulin Action
Strong breed predispositions for DM have been
reported in dogs and support a heritable component to
the disease.39,41–43 As described above, immune system
genes might play a role, but undiscovered genetic causes
of DM in dogs remain. To our knowledge, primary sus-
ceptibility genes for MODY in people have not been
evaluated in dogs. A genome-wide study identified a
chromosomal locus associated with serum fructosamine
concentrations in Belgian Shepherds.44 A causative
mutation was not discovered, but positional genes
involved in glucose metabolism and insulin signaling
(GAPDH and LETM) were implicated.
Several of the canine breeds reported to be at
increased risk for DM also are at high risk for other
predisposing conditions. For example, Yorkshire terri-
ers, Fox terriers, and Miniature schnauzers are predis-
posed to DM and also are at risk for pancreatitis.45,46
Miniature Schnauzers also are prone to familial hyper-
lipidemia,47 which could contribute to the breed’s DM
risk either directly or by the effect of hyperlipidemia on
pancreatitis risk. In conclusion, although genetic predis-
position is likely an important factor in DM in dogs,
these studies do not lend support for one specific etiol-
ogy, but rather suggest that DM in dogs comprises
heterogeneous disorders.
DM Secondary to Diseases of the Exocrine
Pancreas in Dogs
As in people, an association between pancreatitis and
DM might exist in dogs.46,48–51 In one histopathologic
study, approximately 33% of diabetic dogs had evidence
of concurrent pancreatitis.28 In another study, histop-
athologic evidence of chronic pancreatitis was found in 6
of 18 diabetic dogs and acute pancreatitis was found in 5
of 18.33 In contrast, other studies on diabetic dogs have
found histopathologic evidence of pancreatitis to be
lacking or rare.31,35 In both dogs and people, it is diffi-
cult to identify a cause and effect relationship between
DM and pancreatitis, and both could result from the
same primary disease process. Human patients with
T2DM have 1.5–1.8 fold increased risk of developing
acute pancreatitis,52,53 and both insulin resistance and
hyperglycemia might be key factors in this process.54
Mild hyperglycemia occurs frequently in nondiabetic
people suffering from pancreatitis. This observation previ-
ously was considered unimportant because hyperglycemia
normalizes after pancreatitis subsides. Recently, however,
a higher risk (2.7-fold) of developing prediabetes and DM
within 5 years was demonstrated in previously nondia-
betic people who have suffered an episode of acute pan-
creatitis.55 In dogs, insulin secretion (assessed by glucagon
stimulation) was impaired in 5 of 6 dogs with pancreatitis
despite being euglycemic before stimulation.56
DM Secondary to Endocrinopathies and
Gestational DM in Dogs
In contrast to Gestational DM in people, there is no
evidence in dogs that developing overt DM during
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pregnancy increases risk for complications in the bitch
or pups. As in people, gestation is associated with
increased insulin resistance in the bitch, but the mecha-
nism is different. In dogs, progesterone stimulates the
mammary gland to produce growth hormone (GH)
and release it into the systemic circulation. Increased
GH leads to insulin resistance.57 The term Gestational
DM probably is inappropriate in dogs. Regardless of
source and timing, increased exposure to progesterone
in the dog leads to increased GH secretion in the
mammary glands whether during gestation, diestrus, or
as a consequence of exogenous administration of
progestins.24,57,58 Therefore, the term progesterone-
controlled GH overproduction DM (PGHDM) might
be more appropriate,58 and this disorder should be
classified as DM secondary to an endocrinopathy.
Also, in contrast to Gestational DM in people, there is
limited evidence in dogs that underlying b-cell dysfunc-
tion is present before gestation. Rather, increased GH
might result in such extreme insulin resistance that it
alone causes DM.
It is unknown whether PGHDM dogs that go into
remission remain at high risk for developing future DM
independently of subsequent exposure to progesterone
(suggesting that b-cell disease was present before expo-
sure). However, dogs that go into remission at the end
of diestrus and that are not spayed are likely to become
overt diabetics during future cycles.24 Also unknown is
the risk that repeat exposure to high GH through
estrous cycles confers on future development of DM in
dogs. In 1 study that prospectively assessed 84 nondia-
betic intact female dogs, only 1 dog developed DM
after 2 years and no conclusions could be drawn
regarding the risk conferred by increased concentrations
of GH, IGF-1, and markers of insulin resistance on the
development of DM.57
DM Secondary to Hypercortisolism in Dogs
Glucocorticoids cause insulin resistance, but they
also affect b-cell function by decreasing insulin secre-
tion, blunting the incretin effect and by direct cytotox-
icity.59–62 In one study, only 8% of dogs with
hypercortisolism had overt DM by traditional criteria,
but 38% of dogs had moderate hyperglycemia63 and
would have been classified as having DM based on
the criteria suggested above. Similar to PGHDM, it is
unknown why some dogs with hypercortisolism
develop DM and others do not. Does the difference
lie in severity of or sensitivity to hypercortisolism, or
does it lie in a primary pancreatic lesion that prevents
adequate compensation for insulin resistance caused
by glucocorticoids? If hypercortisolism merely exposes
a pre-existing pancreatic lesion (caused by any one the
other etiologies of DM) in these dogs, then the preva-
lence of DM in dogs with hypercortisolism should be
much more similar to the prevalence of DM in the
general population.41,63 However, it is possible that
hypercortisolism merely exposes a pre-existing pan-
creatic lesion that would have otherwise remained
subclinical.
The Importance of Early and Accurate Diagnosis
of Mature-Onset DM in Dogs
Accurate diagnosis early in the course of a disease
can be important in slowing or preventing progression
of the disease. Immune modulation in T1DM before
extensive loss of b-cell mass could become a viable pre-
ventive strategy in the near future, but it would require
accurate classification and early diagnosis of DM.5
Strategies for early detection of b-cell loss in humans
with T1DM (before detection of glucose intolerance)
are being developed.64
Exclusion of an autoimmune process in a patient with
DM and concurrent (or resultant) pancreatitis might
have clinical relevance in the early management. The
pancreatic inflammatory process combined with tran-
sient glucotoxicity could perpetuate injury to b-cells and
cause permanent damage. Therefore, it might be possi-
ble to prevent establishment of permanent DM in some
dogs by glycemic normalization near the time of
diagnosis.
Accurate diagnosis also could affect treatment strate-
gies in the established diabetic patient. Most impor-
tantly, the risk of life-threatening hypoglycemia might
be different in animals with an isolated disease of pan-
creatic b-cells (as in T1DM) as compared to animals
with a disease process involving other cells types in the
islets of Langerhans (as in DM secondary to diseases of
the exocrine pancreas). Decreased glucagon secretion
from damaged, dysfunctional, or absent a-cells would
increase susceptibility to exogenous insulin overdosage
and might necessitate a more conservative approach to
treatment. Alternatively, pancreatic polypeptide (PP)
deficiency might affect hepatic sensitivity to insulin. In
dogs, the liver is a primary site for developing insulin
resistance,65 and PP increases hepatic insulin sensitiv-
ity.66,67 Pancreatic polypeptide deficiency has been iden-
tified in people with chronic pancreatitis and in rodent
models, and could contribute to the development of
DM.67 Identifying this deficiency in a diabetic patient
could have implications for treatment such preference
for a “hepato-selective” insulin formulation (eg, insulin
detemir).68 In the few studies that have described the
histopathologic abnormalities in the pancreatic islets of
DM dogs, a decreased number of b-cells paralleled a
reduction in other cell types in the islets; a complete
absence of islets was frequently reported but a detailed
characterization of all cell types in the islets was not
performed.28,31,33 Further scrutiny of the distribution of
different islet cell types and the involvement of islet-
produced hormones (eg, glucagon) in various types of
DM in dogs is necessary.
In dogs treated for pituitary-dependent hypercorti-
solism with retinoic acid, the rate of progression from
IFG (105–168 mg/dL [5.8–9.3 mmol/L]) to DM
(BG > 168 mg/dL [9.3 mmol/L]) was significantly lower
in those additionally treated with a low dosage of insu-
lin detemir (0.1 U/kg q24h) as compared to those not
treated with insulin.63 This study lends support to the
hypothesis that defining and treating subclinical dysg-
lycemia could delay or prevent overt DM in dogs. It
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also suggests that low doses of insulin detemir are
useful and safe in regulating glycemia in dogs with only
mildly increased BG. Another potential safe and
effective treatment strategy could be the use of
glucagon-like peptide-1(GLP-1)-receptor agonists. The
GLP-1-receptor agonists effectively maintain a nonin-
sulin-dependent state in people with DM and have been
shown to protect b-cells from cytotoxicity caused by
glucocorticoids.60
Juvenile-Onset DM in Dogs
Reports of DM in young dogs are uncommon.69–76
Most reports describe insulin-dependent dogs with vari-
ous histopathologic abnormalities of the pancreas, but
no clear etiology. Similar to neonatal DM in humans,
none of the reported cases of juvenile-onset DM in dogs
were thought to be immune-mediated based on
histopathology. Pancreatic islet lesions described include
atrophy, aplasia, or hypoplasia, or inflammation of the
exocrine pancreas. Congenital hypoplasia of islet b-cells
has been described in Keeshond puppies, but solitary
b-cells still were present.72 Similar findings were
described in a Chow and a Brittany Spaniel.70,74 In the
diabetic Keeshond, insulin concentration in the pan-
creas was markedly decreased, and glucagon concentra-
tion also was decreased (approximately 33% of
normal). Despite this finding, glucagon response to argi-
nine was normal.72 DM inheritance was suspected to be
autosomal recessive, but no specific genetic mutation
was identified.71 In young Greyhounds, German Shep-
herds and Golden Retrievers, DM has been associated
with atrophy of the exocrine pancreas70,73 and exocrine
pancreatic insufficiency.75,76
As discussed above, mutations in genes encoding the
KATP channel are the most common cause of neonatal
DM in people, and these patients can be treated with
sulfonylurea orally. Limited data are available to sup-
port monogenic causes of DM in dogs, and possibly a
subset of diabetic puppies suffer from mutations similar
to those described in humans. Such puppies could
become insulin-independent with proper treatment
selected based on the specific genetic etiology. One vet-
erinary report indicated that no mutations were found
in the human neonatal DM susceptibility gene KCNJ11
in dogs, but the data itself were not presented.43
Prediabetes in Dogs
Currently, there is no established definition for the
diagnosis of prediabetes in dogs, and no prospective
studies have demonstrated the utility of any diagnostic
test in predicting the development of diabetes. As men-
tioned above, biomarkers for detection of b-cell death
are being developed and might aid in early detection of
T1DM in dogs. Abnormal insulin secretory response to
glucagon stimulation (as detected in patients with pan-
creatitis)56 might prove to be a marker of prediabetes in
dogs but must be confirmed with prospective studies.
Validation of PO or IV glucose tolerance tests in dogs
could also facilitate a diagnosis of prediabetes.
DM in Cats: Breaking Down the Type 2
Umbrella
Specific criteria for a diagnosis of DM in cats have
not been agreed upon, in part for similar reasons as
explained above for dogs, but with the additional diffi-
culty caused by the prevalence of stress hyperglycemia
in cats. To enable clinicians and researchers to better
compare study and treatment results in the future, we
propose that DM in the cat be more clearly defined.
Importantly, an RI study of serum fructosamine in cats
should be performed, generating separate RIs for male
and female cats, and standardization across laboratories
should be attempted.77 Alternatively, a similar approach
could be considered but with a feline glycosylated
hemoglobin assay. These steps would allow incorpora-
tion of serum fructosamine or glycosylated hemoglobin
into the definition of prediabetes, subclinical DM, and
overt DM in cats. Without an accurate indicator of
long-term glycemia (fructosamine or glycosylated hemo-
globin), it is difficult to recommend a new definition
that encompasses all of these stages. Although there are
no comprehensive RI studies for BG in cats, multiple
studies in adult healthy cats consistently show fasting
BG do not exceed 126 mg/dL (7 mmol/L).78–83 Thus,
we propose that overt DM in cats be defined as docu-
mentation of a persistently increased fasting
BG ≥ 126 mg/dL (7 mmol/L), supported by documen-
tation of elevated fructosamine or glycosylated hemo-
globin, regardless of clinical signs attributable to a
pathologic excess of circulating glucose.
Based on clinical presentation, epidemiology, genetic
research and association with islet amyloid deposits,
DM in cats previously has been classified as a
T2DM.22,84 As in T2DM in people, obesity and physi-
cal inactivity are major risk factors for DM in cats.85,86
Also similar to T2DM in people is the age of disease
onset (diabetic cats often are older) and the potential
for insulin independence. Based on these features and
because T2DM is an umbrella term that includes
unknown etiologies, type 2 indeed might be an appro-
priate category for most diabetic cats. However, when a
disease such as hypersomatotropism is present, by defi-
nition T2DM is excluded, and DM should be classified
as “secondary to an endocrinopathy”.
From a clinical perspective, therapy and remission
rates differ between T2DM and DM secondary to endo-
crinopathies, and from a research perspective, differenti-
ating between these types of DM might help with the
discovery of underlying etiologies for T2DM. Also, as
mentioned above, a precise diagnosis early in the course
of the disease might be important in preventing or slow-
ing progression.
T1DM in Cats
Significant lymphocytic infiltration of the endocrine
pancreas, as evidence of cell-mediated autoimmune
destruction of b-cells, has been reported in only a
handful of diabetic cats. Also, there are no reports of
naturally occurring insulin or b-cells autoantibodies in
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cats. Thus, if T1DM occurs in cats it is probably
rare.22
DM Secondary to Diseases of the Exocrine
Pancreas in Cats
Diabetes mellitus in cats often is associated with
abnormalities in serum markers of exocrine pancreatic
disease.87–89 A weak positive correlation between feline
pancreatic lipase activity (fPLI) and serum fructosamine
was reported in cats with DM, suggesting that sub-
clinical pancreatitis might cause inadequate glycemic
control.88 Alternatively, inadequate glycemic control
(reflected by increased serum fructosamine) might cause
ongoing damage to the exocrine pancreas (reflected by
increased fPLI), as suggested by an experimental study
in which pancreatic neutrophils increased in healthy
cats with experimentally induced hyperglycemia.90 The
fact that most diabetic cats with increased fPLI do not
have gastrointestinal signs and are not less likely to
achieve remission further argues in favor of inadequate
glycemic control as the cause of increased fPLI.88,89,91
Similarly, T2DM in people is considered a risk factor
for pancreatitis.52–54 In contrast, based on histopathol-
ogy, the frequency of pancreatitis is similar in diabetic
cats and control cats suggesting no cause and
effect.87,92–94 Therefore, the majority of evidence (from
feline and human clinical and experimental models)
points to DM being the cause rather than the result of
the abnormalities in the exocrine pancreas. The possibil-
ity that in some cats pancreatic disease causes DM can-
not be excluded, but this outcome seems relatively
uncommon.
DM Secondary to Endocrinopathies in Cats
Several endocrinopathies have been associated with
DM in cats. The most important are hypersoma-
totropism (excess production of growth hormone usu-
ally caused by a benign tumor of somatotrophs of
anterior pituitary gland) and hypercortisolism (cortisol
excess from an adrenal or pituitary tumor, or iatro-
genic). Naturally occurring hypercortisolism is rare in
cats. In contrast, hypersomatotropism-induced DM is
common. Recently, 1,221 diabetic cats were screened in
first opinion practices in the United Kingdom and 26%
were found to have serum insulin-like growth factor-1
concentrations (IGF-1) > 1,000 ng/mL.95 Of these cats,
63 (20%) were further evaluated, including intracranial
imaging, postmortem evaluation, or both. Based on
these 63 cats, IGF-1 had a positive predictive value of
95%, confirming the prevalence of hypersomatotropism
among UK diabetic cats to be 25%.95 Interestingly,
only 1 in 4 attending clinicians originally strongly sus-
pected hypersomatotropism in cats subsequently diag-
nosed with the disease, suggesting that many affected
cats present with DM but otherwise lack readily identi-
fiable signs of acromegaly. The investigators suggested
use of the term hypersomatotropism over acromegaly
because the latter implies the presence of physical fea-
tures indicative of GH excess.95
Because of the high prevalence of hypersoma-
totropism in cats with DM, routine measurement of
IGF-1 is recommended, regardless of clinical presenta-
tion. This practice is especially important because timely
diagnosis might have major impact on the understand-
ing of an individual cat’s DM, ideal treatment modali-
ties and ultimate outcome. Treatment with the
somatostatin analogue pasireotide96, radiotherapy97 or
hypophysectomy98 has shown that when the underlying
GH excess is properly managed, glycemic control can
improve dramatically. Diabetic remission rates as high
as 85% have been achieved in diabetic cats with
hypersomatotropism treated by hypophysectomy.98
Such high remission rates, even in cats that have been
diabetic for several years, suggest that diabetic cats with
hypersomatotropism might not suffer from intrinsic
b-cell pathology. Nevertheless, early treatment of hyper-
somatotropism is prudent considering the inevitable and
ultimately negative sequelae of glucotoxicity on the
b-cells. High rates of DM remission in treated hypersoma-
totropism also are indirect evidence of intrinsic b-cells
pathology in diabetic cats without hypersomatotropism.
In such cats, with current treatment recommendations
remission rates usually are much lower and remission is
only temporary in approximately 30% of cases.82,99
Secondary DM occurs in approximately 80% of cats
with spontaneous hypercortisolism (in contrast to only
8% in dogs).64,97 Additionally, previous exogenous expo-
sure to glucocorticoids is a risk factor for DM in cats.
Increased insulin resistance from glucocorticoid excess
could cause cats with subclinical DM to progress to an
overt stage. Most cats treated with high dosages of gluco-
corticoids do not develop DM, supporting the theory of
a pre-existing subclinical DM state in those cats that do
develop glucocorticoid-induced DM. On the other hand,
diabetic cats with a previous history of glucocorticoid
administration are more likely to achieve diabetic
remission.99 Additional research is needed to clarify the
relationship between glucocorticoids and DM in the cat.
Prediabetes in Cats
Currently, there are no established definitions for the
diagnosis of prediabetes in cats. Despite the association
of DM with obesity in cats, obesity cannot be used as a
criterion for diagnosis of prediabetes because most
obese cats do not develop DM. Additional mechanisms
must be necessary for obese cats to become diabetic.
For example, a melanocortin receptor-4 polymorphism
is overrepresented in obese compared to lean diabetic
cats and could be a contributing risk factor.100 In peo-
ple, although obesity is considered a primary risk factor
for T2DM, its presence is only useful in first-line screen-
ing for prediabetes and it is not effective as the sole
screening metric. This is because obesity reflects insulin
resistance, which in itself does not lead to DM unless
pancreatic dysfunction also is present. In contrast, pre-
diabetes implies pancreatic dysfunction, with or without
insulin resistance.
Surrogate markers of pancreatic dysfunction that
assess glucose tolerance (eg, fasting BG, glucose
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tolerance tests, glycosylated hemoglobin, fructosamine)
are better predictors of progression to DM than mea-
sures of obesity and insulin resistance, and are used to
screen people (eg, obese, pregnant) at risk for DM.1
None of these surrogate markers exclusively reflects
b-cell dysfunction, and none indicates an irreversible
disease process. Therefore, these markers are not 100%
predictive. Glucose intolerance might be a reflection of
insulin resistance, b-cell dysfunction, or often, a combi-
nation of both.
Several studies report on glucose intolerance in cats
as demonstrated by IV and PO administration of glu-
cose.79,80,101 In general, these studies have identified
abnormalities in overweight and obese cats, although
abnormalities in lean cats also have been detected. Nev-
ertheless, no prospective longitudinal studies have deter-
mined the utility of any diagnostic test in predicting the
development of overt DM in cats. Studies on glucose
intolerance in cats leave 2 clinically relevant questions
unanswered: 1. Assuming prediabetes can be character-
ized by glucose intolerance, is this glucose intolerance
predictive of development of DM? and 2. Is the diagno-
sis of glucose intolerance more predictive of developing
DM than other more easily measurable parameters such
as body weight, body condition score, or body mass
index?
To be predictive of DM, a diagnosis of prediabetes
should detect subclinical b-cell pathology and not be
made based on tests that merely reflect the normal
physiology of the cat. The glucose intolerance identified
in some studies might not represent pathology but
rather a normal response to a supra-physiologic glucose
load. The response often is wrongly considered patho-
logic because of extrapolation from the normal response
in other species, particularly humans. Cats are obligate
carnivores and have evolved to handle glucose differ-
ently than the omnivorous animal models (eg, human,
dog, mouse). For example, cats cannot sense dietary
sugars because of mutations in Tas1r2, the gene that
encodes a subunit of the sweet receptor.102 If the ability
to sense glucose (which is important in glucose regula-
tion in other species) is used as a test to identify glucose
intolerance, all cats will fail the test. Clearly, such a test
has no predictive value for the diagnosis of DM in cats.
Similarly, when glucose is administered PO in tolerance
tests, the ability of the normal cat to handle a glucose
load should be taken into account. When glucose is
added to a high-protein diet at 2 g/kg, prolonged and
excessive hyperglycemia (>180 mg/dL [10 mmol/L])
occurs in healthy cats.103 However, this outcome is
expected because healthy cats, in contrast to dogs and
people, do not secrete the incretin hormone GIP
(glucose-dependent insulinotropic peptide) in response
to orally administered glucose.78,104 Therefore, this so-
called “glucose intolerance” is a normal response and
unlikely to be predictive of prediabetes.
Glucose intolerance as measured by abnormal hyper-
glycemia after PO administration of glucose was
demonstrated in obese (compared to lean) cats with
2 g/kg glucose (administered via gastric intubation).
Whether this was the result of insulin resistance
exclusively or also the result of b-cell dysfunction was
not elucidated.80 Decreased GLP-1 concentrations also
were reported in the obese cats, consistent with changes
seen in diabetic people. However, GLP-1 secretion
could not be assessed accurately in that study because
of methodologic problems in its measurement.105
Importantly, even if the PO administration of glucose
at this high dosage is a useful test to predict DM, it is
unlikely to be clinically applicable because of the need
for gastric intubation as well as the high frequency of
adverse effects such as vomiting and diarrhea.80
Incretin hormones have a central role in the patho-
physiology and early detection of DM.106 Intravenous
glucose tolerance tests (IVGTT) are therefore inferior to
oral glucose tolerance test because they do not assess
the incretin effect. Glucose intolerance as measured by
IVGTT has been detected in obese cats.79,101 Insulin
concentrations during the first 10 minutes of the
IVGTT are dependent almost entirely on b-cell func-
tion. Blunting of this “first phase” insulin response
(FPIR) in people is characteristic of prediabetes and
DM but this blunted FPIR is not seen in nondiabetic
obese subjects.7 In cats, lean and obese, FPIR is
decreased or absent relative to the response seen in peo-
ple.79,101,107,108 This could be the result of a relatively
low sensitivity of b-cells to glucose stimulation in cats
when compared to people.109 In 2 studies, there was a
trend in obese cats toward lower or even absent FPIR
compared to lean cats, suggesting that, with obesity,
b-cell function decreases in cats.79,101 Neither of these
studies followed the obese cats to determine if they later
developed DM.
In summary, the lack of GIP response to PO glucose,
decreased sensitivity to an acute increase in BG
(blunted FPIR) and other physiologic peculiarities, con-
tribute to the cat’s inability to handle large glucose
loads (whether IV or PO) and cause the appearance of
“glucose intolerance”. This could limit the usefulness of
these tests in our efforts to define and diagnose predia-
betes in cats as in terms of differentiating individuals at
high risk of progression to overt DM as compared to
individuals not at high risk.
In the past few years, HbA1c has been employed as a
screening methodology for prediabetes in people. There
is no specific cutoff for the presence of prediabetes, but
rather the higher the HbA1c, the greater the risk of
DM. Glycosylated hemoglobin or serum fructosamine
or both might be useful in cats, as they are in people,
as predictors of DM. It remains to be determined how-
ever whether these parameters are sensitive enough for
this purpose. In a study of nondiabetic cats that were
infused with dextrose for several weeks, mild hyper-
glycemia resulted in a noticeable increase in serum fruc-
tosamine from the middle of the reference range to the
upper end of the reference range used in that study.110
As mentioned before, there is no well-established RI for
serum fructosamine in cats77 and laboratory methods
vary across institutions. Furthermore, no longitudinal
studies have evaluated the utility of serum fructosamine
in predicting DM. In another study of nondiabetic cats
(all with serum fructosamine within the reported normal
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range), a weak but significant correlation was found
between serum fructosamine and body weight, and male
cats had higher serum fructosamine than did female
cats (even after adjusting for body weight differences).77
Overweight male cats are at high risk of developing
DM,111 and higher serum fructosamine in these cats
could be the result of a subgroup being prediabetic and
having less than ideal glycemic control. Whether or not
this is true needs to be determined in follow-up studies.
Final Remarks
Classification of DM in humans has been refined sub-
stantially over the past decade and has required clini-
cians and researchers to take into account the diversity
of underlying disease processes that are being grouped
under the broad umbrella term of DM. This proactive
approach toward better understanding of the different
types of DM has decreased the number of misdiag-
noses, and most importantly, enabled the adoption of
the most appropriate treatment modalities specifically
suited to the particular underlying disease process. A
uniformly accepted classification system has been lack-
ing in veterinary medicine, as have specific definitions
of companion animal DM itself and the concept of pre-
diabetes in companion animals. We hope this review
stimulates work toward adopting a similar classification
system in veterinary medicine, based on increasing
knowledge of the underlying disease mechanisms. We
also hope the suggested adaptation of the ADA system
soon will become outdated, reflecting increased under-
standing of DM in companion animals. Such increased
understanding likely will lead to better treatment prac-
tices, higher remission rates, and, ultimately increased
animal welfare.
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